Drug Trial Radar · NCT02118896
Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant
Last checked: Nov 20, 2026Latest source record: Nov 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
850
Actual
Start
Feb 24, 2003
Primary completion
Oct 7, 2009
Study completion Oct 7, 2009
Sponsor
- Lead sponsor
- Astellas Pharma Europe Ltd.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Apr 21, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to offer patients who had participated in one of the phase II PK or phase III studies on FK506E (MR4) the possibility to continue FK506E (MR4) until commercial availability of the drug and to record long term efficacy and safety data.
Conditions
- Heart Transplantation
- Liver Transplantation
- Kidney Transplantation
Interventions
FK506EDrug
oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participant SurvivalTime frame: Up to 5.5 years (66 months (phase II) and 24 months (phase III)).
- Graft SurvivalTime frame: Up to 5.5 years ((66 months (phase II) and 30 months (phase III)).
Locations
105 sites in 23 countries. Site status is shown where the registry gives one.
University Hospital
Cincinnati, Ohio
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Princess Alexandra Hospital
Brisbane, Queensland, Australia
Austin Hospital
Heidelberg, Victoria, Australia
Royal Melbourne Hospital
Melbourne, Victoria, Australia
Landeskrankenhaus Innsbruck
Innsbruck, Austria
AKN Wien
Vienna, Austria
Hospital Erasme
Brussels, Belgium
Cliniques Universitaires St. Luc
Brussels, Belgium
Departement Heelkunde
Ghent, Belgium
Universitair Ziekenhuis Gasthuisberg
Leuven, Belgium
Domaine Universitaire du Sart Tillman
Liège, Belgium
Hospital da Clínicas da UNICAMP
Campinas, Brazil
Hospital São Francisco
Porto Alegre, Brazil
Irmandade da Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Brazil
Hospital Geral de Bonsucesso
Rio de Janeiro, Brazil
Vancouver Hospital & Health Sciences Centre
Vancouver, Canada
University of Alberta
Edmonton, Alberta, Canada
London Health Sciences Centre
London, Ontario, Canada
University of Ottawa Heart Institute
Ottawa, Ontario, Canada
Institut de Cardiologie de Montréal
Montreal, Quebec, Canada
Centre Hospitalier de l'Universite de Montreal (CHUM)
Montreal, Quebec, Canada
Royal Victoria Hospital
Montreal, Quebec, Canada
IKEM
Prague, Czechia
Skejby University Hospital
Århus N, Denmark
Helsinki University Central Hospital
Helsinki, Finland
Hôpital Beaujon
Clichy, France
Hôpital Henri Mondor
Créteil, France
Hôpital Henri Mondor
Créteil, France
Chu Nord
Grenoble, France
CHU Saint-Etienne
Saint-Etienne, France
Hôpital Hautepierre
Strasbourg, France
Hopital Paul Brousse
Villejuif, France
Hôpital Bicêtre
Le Kremlin-Bicêtre, Bicetre Cedex, France
Hôpital Calmette
Lille, Cedex, France
Hopital Pontchaillou
Rennes, Cedex, France
Hopital Saint-Eloi
Montpellier, Cedex 05, France
Hopital Laennec
Nantes, Cedex 1, France
Hotel Dieu
Nantes, Cedex 1, France
Service de Nephrologie
Nice, Cedex 1, France
Showing 40 of 105 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.